Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Por Gadgeel, S, Peters, S, Mok, T, Shaw, A T, Kim, D W, Ou, S I, Pérol, M, Wrona, A, Novello, S, Rosell, R, Zeaiter, A, Liu, T, Nüesch, E, Balas, B, Camidge, D R
Publicado no Ann Oncol (2018)

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Por Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Publicado no Ann Oncol (2018)